Tag: Antidepressant Withdrawal

  • Psychiatry Is on Trial. We Should Not Plead Guilty to the Wrong Charges

    Psychiatry Is on Trial. We Should Not Plead Guilty to the Wrong Charges

    Psychiatry is on trial. It was probably inevitable. A field that treats suffering, suicide, psychosis, trauma, addiction, violence risk, loneliness, despair, and meaninglessness was always going to be dragged into the political arena. Psychiatry sits at the intersection of medicine, culture, family trauma, public fear, pharmaceutical influence, personal liberty, and moral injury. That makes it uniquely vulnerable to distortion.

    But the current moment feels different.

    With Health and Human Services Secretary Robert F. Kennedy Jr. placing psychiatric medications and “overmedicalization” at the center of federal attention, psychiatry is no longer only being debated in journals, clinics, and academic conferences. It is being litigated in public. Increasingly, it is also being litigated in court. On May 4, 2026, HHS announced a MAHA action plan aimed at curbing psychiatric overprescribing, promoting informed consent, shared decision-making, nonmedication interventions, and deprescribing when clinically indicated.1

    Some of that language is reasonable. In fact, many psychiatrists already agree with it.

    Psychiatric medications should not be the default response to every form of human distress. Patients deserve informed consent. Deprescribing should be part of competent care. Psychotherapy, exercise, sleep, nutrition, family support, social connection, and meaning making should not be treated as decorative add-ons. They are often central to recovery.

    But that is not the same as saying psychiatric illness is not real. It is not the same as implying psychiatric medications are broadly dangerous, unnecessary, or responsible for America’s mental health crisis. And it is certainly not the same as turning painful anecdotes into national policy.

    That is where psychiatry must draw the line.

    The American Psychiatric Association has appropriately pushed back on the idea that the mental health crisis can be reduced to overprescribing, noting that this framing ignores workforce shortages, limited access to care, lack of psychiatric beds, and uneven distribution of evidence-based treatment.2 That is exactly right. Deprescribing may be good medicine in selected cases. But deprescribing is not a national mental health strategy.

    It is a clinical tool.

    There is a dangerous pattern in the current conversation. A public figure describes a deeply personal experience: a family member struggles to discontinue an antidepressant, someone feels emotionally blunted on medication, a young adult regrets being started on an SSRI as a teenager, or a patient develops withdrawal symptoms after stopping too quickly. The story is real. The suffering is real. The problem deserves attention.

    But then the anecdote becomes a theory of psychiatry.

    The assumption becomes: because this happened to someone I love, this must be what psychiatry is doing to the country.

    That is not science. That is narrative capture.

    Psychiatry should not dismiss these stories. We should listen to them. We should admit that antidepressant discontinuation can be difficult for some patients. We should acknowledge that medications are sometimes started without a clear enough plan, continued without adequate review, and stopped too abruptly. We should be honest that some patients are placed on medication when what they needed first was psychotherapy, time, structure, sleep, exercise, substance use treatment, grief work, family intervention, or a change in environment.

    But honesty cuts both ways.

    Some patients are not “overmedicalized.” They are undertreated. Some are not being harmed by psychiatry. They are being harmed by the absence of psychiatry. Some patients do not need fewer medications. They need the right diagnosis, the right medication, the right dose, the right monitoring, the right therapy, and a system that does not abandon them after discharge.

    I work in real-world psychiatry. I have seen patients whose lives were devastated by undertreated depression, bipolar disorder, psychosis, catatonia, OCD, addiction, and trauma. I have also seen patients placed on medications they did not need, for longer than necessary, without enough discussion about risks, benefits, alternatives, or exit strategies. Both realities are true.

    That is the entire point.

    Psychiatry’s critics often want one story. The real world gives us several.

    Psychiatric medications can be overused. They can also be lifesaving.

    Antidepressants can cause side effects. They can also help patients return to work, reconnect with family, survive suicidal depression, and function again.

    Stopping medication can produce withdrawal symptoms. Stopping medication can also reveal relapse of the underlying illness. Clinically, those are not always easy to separate, and the distinction matters.

    Psychiatry has a difficult history. It also remains one of the few medical specialties willing to sit with the most frightening, stigmatized, and disabling forms of human suffering.

    The field does not need denial. It needs precision.

    One of the most important reforms psychiatry should embrace is building the off-ramp into treatment from the beginning. When starting an antidepressant, clinicians should discuss expected duration, criteria for continuation, warning signs of relapse, tapering principles, and what remission means. Patients should know that medication is not a moral failure, not a life sentence, and not something to stop abruptly to prove toughness.

    Abrupt discontinuation is not courage. It is usually bad medicine.

    And it is not only psychiatrists saying so. The American Foundation for Suicide Prevention, responding directly to the HHS action plan, warned that “abrupt discontinuation or inappropriate ‘deprescribing,’ particularly outside a collaborative patient-provider process, can increase risk, including the potential for symptom relapse and elevated suicide risk for some individuals.”3 AFSP also reaffirmed what decades of clinical trials, population-level studies, and health system data have shown: judicious use of antidepressants reduces suicide risk overall.3

    That is the suicide prevention community speaking. Not the pharmaceutical industry. Not organized psychiatry. The organization whose entire mission is keeping people alive.

    If HHS wants to support better tapering education, better informed consent, better access to psychotherapy, and better reimbursement for clinicians who take the time to deprescribe carefully, psychiatry should welcome that. In fact, we should lead it. The HHS action plan specifically emphasizes informed consent, shared decision-making, review of risks and benefits, nonmedication approaches, and tapering when patients are not experiencing clinical benefit.1 Those are not anti-psychiatry principles. Done correctly, they are good psychiatry.

    But the same public conversation has also entertained the claim that psychiatric medications cause mass shootings, a claim that has been repeatedly examined and found to lack credible scientific support. When prominent voices repeat it anyway, the harm is not abstract. Patients hear it. Families hear it. Lawmakers hear it. People already afraid of treatment become more afraid. Stigma grows. Care is delayed.

    And delayed care kills. AFSP said as much in its response to this action plan.3

    Psychiatry should not respond to this moment by becoming reflexively defensive. We should not pretend the field has always gotten it right. We have not. We should not deny withdrawal, side effects, diagnostic uncertainty, pharmaceutical influence, rushed prescribing, or the medicalization of ordinary distress. Those criticisms contain enough truth that ignoring them would be a mistake.

    But we should also refuse to accept a false indictment.

    The problem is not that psychiatry exists. The problem is that too many Americans receive fragmented, rushed, algorithmic, poorly monitored, under-resourced mental health care and then call that psychiatry.

    The problem is not that antidepressants are prescribed. The problem is that they are sometimes prescribed without enough diagnostic clarity, psychotherapy access, follow-up, deprescribing planning, or attention to the difference between illness and distress.

    The problem is not that psychiatrists believe in medication. The problem is that our health care system often reimburses medication management more reliably than psychotherapy, family work, lifestyle intervention, prevention, community support, and time.

    That is not an argument against psychiatry. It is an argument for better psychiatry.

    Psychiatry must be willing to say something politically inconvenient: not all suffering is mental illness, but mental illness is real. Not everyone who is sad needs a diagnosis, but some people with depression will die without treatment. Not every anxious child needs medication, but some children are severely impaired and deserve evidence-based care. Not every patient should remain on an antidepressant indefinitely, but some patients relapse repeatedly when treatment is stopped. Not every psychiatric outcome is preventable, but some bad outcomes occur because systems fail.

    It is possible to do everything right in psychiatry and still have a tragic outcome.

    It is also possible to have a tragic outcome because we did not do enough.

    That distinction is where serious medicine lives.

    This is why psychiatry must reclaim the public narrative. We cannot allow the field to be defined only by its critics, by pharmaceutical marketing, by political theater, or by the most extreme anecdotes on social media. We need to speak plainly to the public.

    Yes, antidepressant withdrawal can happen.

    Yes, some patients are overmedicated.

    Yes, informed consent needs to improve.

    Yes, therapy and lifestyle interventions matter.

    Yes, deprescribing should be part of psychiatric competence.

    And yes, psychiatric medications remain essential treatments for many people with serious and disabling illness.

    The future of psychiatry should not be pill-first. It should not be pill-never. It should be patient-first, diagnosis-first, evidence-first, and humility-first.

    Psychiatry will not survive this moment by going quiet, and it will not survive it by going defensive. It will survive by becoming better, and by saying so out loud.

    We are not the cause of America’s mental health crisis. We are also not its cure. We are physicians treating the most disabling illnesses medicine has ever named, in a system that has never funded us to do it well, in a country that wants the suffering to stop but does not want to pay for the treatment that stops it.

    If HHS wants better psychiatry, psychiatry should be the first to demand it. If patients want safer prescribing, we should be the ones leading it. If the public wants honesty, we should give them more of it than they expected.

    Psychiatry does not need to plead guilty to the wrong charges. But we do need to stop letting other people write the indictment.

    The defense rests when the work begins.

    References

    1. HHS launches MAHA action plan to curb psychiatric overprescribing. US Department of Health and Human Services. News release. May 4, 2026. Accessed May 13, 2026. https://www.hhs.gov/press-room/hhs-launches-maha-action-plan-curb-psychiatric-overprescribing.html

    2. APA welcomes national focus on mental health, urges evidence-based approach and continued focus on access to care. American Psychiatric Association. News release. May 4, 2026. Accessed May 13, 2026.

    3. Moutier CY. AFSP statement on the importance of antidepressants and evidence-based treatment for suicide prevention. American Foundation for Suicide Prevention. News release. May 5, 2026. Accessed May 13, 2026. https://www.prnewswire.com/news-releases/afsp-statement-on-the-importance-of-antidepressants-and-evidence-based-treatment-for-suicide-prevention-302762738.html

    4. Espí Forcén F, Hatters Friedman S. Psychiatry on trial: are psychiatrists responsible for their patients’ criminal behavior? Psychiatric Times. August 27, 2026. Accessed August 29, 2026. https://www.psychiatrictimes.com/view/psychiatry-on-trial-are-psychiatrists-responsible-for-their-patients-criminal-behavior

    Disclaimer: Views are my own not associated with any employer. This is not medical advice, and the information is provided for educational purposes only. Please consult your doctor for any specific medical questions. All content is created for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider. If you think you have a medical emergency, call your doctor, go to the emergency department, or call 911. We do not endorse any specific treatment, tests, or procedures. Reliance on this information is solely at your own risk.

  • Is Antidepressant Withdrawal Overhyped? What the Evidence Really Says

    Is Antidepressant Withdrawal Overhyped? What the Evidence Really Says

    In my clinical practice, I’ve often found myself scratching my head over the narrative surrounding antidepressant withdrawal.

    I’m not denying that withdrawal is real—it is. And for a small subset of patients, it can be quite distressing. But what I am saying is this: it’s not nearly as common, dramatic, or dangerous as some online circles and sensational stories would have you believe.

    I’ve seen countless patients abruptly stop antidepressants and experience no withdrawal symptoms. I’ve also aggressively tapered antidepressants in patients with bipolar disorder to prevent mood destabilization—again, with little to no evidence of withdrawal. This isn’t a one-off observation. It’s a consistent clinical pattern I’ve noted for years. So, I asked myself: What does the data actually say?

    The Evidence

    A 2024 meta-analysis published in JAMA Psychiatry examined 49 randomized controlled trials and finally gave us some clarity.

    The results?
    ✅ People discontinuing antidepressants reported on average just one more symptom than those who either continued medication or discontinued a placebo.
    ✅ The most commonly reported symptoms in the first two weeks were dizziness, nausea, vertigo, and nervousness—exactly what I’ve seen clinically.
    ✅ Critically, the average number of symptoms fell below the threshold for what’s considered a clinically significant discontinuation syndrome.
    ✅ There was no link between discontinuation and worsening depression, suggesting that if mood symptoms return, it’s likely a relapse—not withdrawal.

    Why This Matters

    There are vocal groups online—often with clear anti-psychiatry agendas—who focus exclusively on rare, severe cases of withdrawal and present them as the norm. The goal is simple: to scare people away from psychiatry and evidence-based treatment using emotional testimonials instead of clinical reality.

    Let’s be honest—those cases do exist, but they are not representative of what most patients experience.

    As clinicians, we should remain cautious and responsible. Yes, we should taper medications thoughtfully. Yes, we should prepare patients for the possibility of withdrawal symptoms. But we also shouldn’t scare them into avoiding treatment—or make them feel trapped on medications for life.

    Bottom Line

    Antidepressant withdrawal can happen. It can be uncomfortable. But it’s rarely severe and almost never dangerous. The fear around it has been overstated by those with an ax to grind. We owe it to our patients to treat based on evidence, not anecdotes.

  • Post-SSRI Sexual Dysfunction (PSSD): An Emerging Concern

    Post-SSRI Sexual Dysfunction (PSSD): An Emerging Concern

    Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), have been a cornerstone of treatment for mood and anxiety disorders for decades. However, as their use has become more widespread, concerns about their side effects—particularly those related to sexual health—have grown. A new wave of attention has focused on Post-SSRI Sexual Dysfunction (PSSD), a phenomenon in which sexual side effects persist even after the discontinuation of SSRI medications.

    What is PSSD?

    It is well-established that up to 50% of patients taking SSRIs experience some degree of sexual dysfunction while on the medication. These effects are usually thought to be transient, resolving within weeks or months after stopping the drug. However, PSSD represents a different and more troubling pattern: persistent sexual dysfunction lasting three months or longer after discontinuing the medication.

    Patients with PSSD frequently report symptoms such as:

    • Genital anesthesia (reduced or absent genital sensation).
    • Anorgasmia (inability to achieve orgasm).
    • Loss of libido (reduced or absent sexual desire).

    In men, erectile dysfunction and ejaculatory issues are common, while women often report reduced arousal and difficulty achieving orgasm. Unlike transient sexual dysfunction, the hallmark of PSSD is its persistence long after the drug has been stopped.

    The Challenge of Evidence

    The evidence supporting PSSD as a formal diagnosis remains limited and primarily consists of:

    • Case reports
    • Case series
    • Observational data, often derived from internet forums and patient advocacy groups

    While these sources highlight distressing patient experiences, they fall at the bottom of the evidence hierarchy. Without randomized controlled trials or large-scale cohort studies, it is impossible to definitively establish causation between SSRI use and PSSD. This lack of robust evidence complicates efforts to understand the true prevalence, biological mechanisms, and risk factors for PSSD.

    Potential Biological Basis

    The exact mechanism of PSSD remains unclear, but hypotheses include:

    1. Serotonin neurotoxicity: Excessive serotonin signaling may lead to long-lasting changes in the central or peripheral nervous systems.
    2. Dopamine suppression: Chronic serotonin elevation may inhibit dopamine pathways, which play a critical role in sexual function.
    3. Receptor desensitization or downregulation: Long-term SSRI use may alter serotonin and other neurotransmitter receptors in ways that persist after discontinuation.

    None of these theories have been definitively proven, and more research is needed to uncover the underlying pathophysiology.

    Prevalence and Diagnosis

    The true prevalence of PSSD is unknown due to the lack of large, high-quality studies. However, anecdotal reports suggest it may be rare but severely impactful for those affected.

    Currently, there are no standardized diagnostic criteria for PSSD. The most common approach involves:

    1. A history of SSRI use.
    2. Persistent sexual dysfunction lasting three months or more after discontinuing the medication.
    3. Symptoms such as genital anesthesia or nipple insensitivity, which are more specific to PSSD compared to general sexual dysfunction.

    What to Do if You Suspect PSSD

    For clinicians and patients encountering persistent sexual dysfunction, it’s essential to first explore modifiable and reversible causes of sexual dysfunction:

    • Lifestyle factors: Obesity, smoking, poor cardiovascular health, and sedentary behavior can contribute to sexual dysfunction.
    • Endocrine issues: Low testosterone or other hormonal imbalances should be evaluated.
    • Medications: Drugs such as finasteride (for hair loss) and isotretinoin (for acne) are also associated with persistent sexual dysfunction and may confound the diagnosis.

    If PSSD remains the primary suspected diagnosis, a timeline of symptoms is crucial. Note when the antidepressant was started, when sexual dysfunction began, and whether the symptoms improved or worsened after stopping the drug.

    The Bottom Line

    PSSD is an evolving area of concern in psychiatry and pharmacology. While current evidence does not definitively prove a causal relationship between SSRIs and persistent sexual dysfunction, the growing number of reports warrants further investigation. Until higher-quality studies emerge, clinicians should approach this condition with empathy and caution.

    Patients experiencing sexual dysfunction should work closely with their healthcare providers to rule out reversible causes and explore management options. For now, the best strategy is awareness, vigilance, and a patient-centered approach to treatment planning.

  • Unintended Outcomes After FDA Pediatric Antidepressant Warnings

    Unintended Outcomes After FDA Pediatric Antidepressant Warnings

    The article “Intended and Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review” examines the effects of the FDA’s 2003-2004 black box warning on antidepressants regarding the risk of increased suicidal thoughts and behaviors in children and adolescents.

    Intended Outcome:

    • The FDA issued the warning to ensure greater awareness of potential risks, encouraging careful monitoring of pediatric patients taking antidepressants.
    • The goal was to reduce suicidal behaviors potentially linked to antidepressant use in younger populations.

    Unintended Outcomes:

    • The warning led to a significant drop in antidepressant prescriptions for children and adolescents.
    • There was a corresponding increase in untreated depression, which may have led to higher rates of suicide attempts and worsening mental health outcomes in some cases.
    • Reduced prescriptions were associated with a decrease in diagnosis and treatment of mood disorders in pediatric populations.
    • The warning inadvertently caused confusion among healthcare providers and parents, often resulting in delays in seeking treatment for depression or anxiety.

    Post-Warning Trends:

    • Follow-up research found no consistent evidence that the use of antidepressants in pediatric patients increases the risk of completed suicides.
    • The decline in antidepressant use and increase in suicidal behaviors during the period following the warning suggest unintended negative consequences of the FDA’s decision.

    Conclusions:

    • While the warning achieved its goal of raising awareness about the risks of antidepressants in children, it also resulted in under-treatment of depression, potentially exacerbating mental health challenges.
    • The article calls for balanced decision-making in pediatric antidepressant use, emphasizing the need for risk-benefit assessments and careful monitoring rather than outright avoidance of antidepressants.

      The FDA’s black box warning led to a reduction in antidepressant use but also to increased untreated mental illness, highlighting the complexities of addressing medication risks in vulnerable populations.

    1. Doctor’s Near-Death Experience: The Truth Behind Antidepressant Withdrawal – Fact or Fiction

      Doctor’s Near-Death Experience: The Truth Behind Antidepressant Withdrawal – Fact or Fiction

      These sensational headlines about near-death experiences coming off antidepressants are becoming far too common. While we must be cautious with prescribing, it’s equally important not to dissuade people from trying medications that could help them.

      Yes, some patients experience withdrawal symptoms if medications are stopped abruptly without proper tapering. But many patients do not, and I’ve seen countless cases where people discontinue their antidepressants without any issues. Some may require prolonged tapers, while others can taper off much faster than alarmist articles would suggest.

      It’s crucial to remember that while discontinuation can be uncomfortable, it’s rarely life-threatening. We do need to be mindful of how long we prescribe these medications, given they manage symptoms but don’t modify the underlying disease, and the long-term benefits are still debated.

      Guidelines for deprescribing are helpful, but dramatic headlines about “nearly dying” when coming off these medications are not only inaccurate but harmful to those who could benefit from treatment. Let’s promote balanced, evidence-based discussion on this topic, focusing on proper discontinuation without sensationalizing the risks.

      Link to article: https://www.theguardian.com/australia-news/article/2024/jul/31/australian-doctor-mark-horowitz-who-almost-died-writes-landmark-guidance-on-how-to-safely-stop-using-antidepressants